By Maxx Chatsko This lab-hardware business is growing, cashed up, and close to profitability. Biotech stocks are mired in a historic correction. That’s not news. What doesn’t receive much discussion is that the correction was largely justified and long overdue. Throughout 2020 and 2021 investors were bombarded with hype from trendy thematic exchange-traded funds and short-lived social-media celebrities. Couple that with share prices that seemed to move only in one direction and a human brain wired for confirmation bias, and it became easy to think, “this time really might be different.” It was…